Combined schedules of pneumococcal conjugate and polysaccharide vaccines: is hyporesponsiveness an issue?

Katherine L. O'Brien, Michael Hochman, David Goldblatt

Research output: Contribution to journalReview article

Abstract

Streptococcus pneumoniae is a major cause of morbidity and mortality in children less than 5 years of age. Prevention of pneumococcal disease and death in children in the developing world through vaccination with recently developed, highly efficacious pneumococcal conjugate vaccines (PCVs) is now possible. Schedules combining PCV with 23-valent pneumococcal polysaccharide vaccine (PPV23) have been studied and proposed as a means to expand disease protection against serotypes not included in the PCVs. Studies of group A and C meningococcal polysaccharide vaccine and repeated doses of PPV23 in adults and children have shown that a state of immune tolerance, or hyporesponsiveness, can develop to repeated polysaccharide vaccine antigen exposures. In this Review, we describe the evidence for and against this hyporesponsiveness and explore the possible mechanisms for such an occurrence.

Original languageEnglish (US)
Pages (from-to)597-606
Number of pages10
JournalLancet Infectious Diseases
Volume7
Issue number9
DOIs
StatePublished - Sep 2007

ASJC Scopus subject areas

  • Infectious Diseases

Fingerprint Dive into the research topics of 'Combined schedules of pneumococcal conjugate and polysaccharide vaccines: is hyporesponsiveness an issue?'. Together they form a unique fingerprint.

  • Cite this